Siga Technologies Inc. (NASDAQ:SIGA – Get Free Report) was the target of unusually large options trading on Wednesday. Stock investors acquired 1,200 call options on the stock. This is an increase of 1,438% compared to the typical daily volume of 78 call options.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered Siga Technologies from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on Siga Technologies
Institutional Trading of Siga Technologies
Siga Technologies Price Performance
NASDAQ:SIGA opened at $4.70 on Thursday. The business’s 50-day moving average is $5.72 and its two-hundred day moving average is $6.56. Siga Technologies has a 12 month low of $4.29 and a 12 month high of $9.62. The firm has a market capitalization of $336.71 million, a PE ratio of 15.16 and a beta of 1.05.
Siga Technologies (NASDAQ:SIGA – Get Free Report) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.08) EPS for the quarter. The company had revenue of $3.79 million during the quarter. Siga Technologies had a net margin of 24.61% and a return on equity of 11.25%. Equities analysts anticipate that Siga Technologies will post 1.04 EPS for the current year.
Siga Technologies Announces Dividend
The company also recently disclosed a special dividend, which will be paid on Thursday, April 23rd. Stockholders of record on Tuesday, April 7th will be paid a dividend of $0.60 per share. The ex-dividend date is Tuesday, April 7th.
About Siga Technologies
Siga Technologies, Inc (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.
Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents.
Recommended Stories
Receive News & Ratings for Siga Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siga Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
